Humpath.com - Human pathology

Most recent articles

• prostatic hyperplasia

  6 June

  prostate hyperplasia
  Types
  prostate adenomatous hyperplasia
  prostate basal cell hyperplasia

• EGFR TKI acquired resistance

  5 June

  Somatic mutations in genes encoding kinases are associated with increased sensitivity of some solid tumors to kinase inhibitors, but patients with metastatic cancer eventually develop disease progression.
  A common method used to model acquired resistance involves culturing parental drug-sensitive cells with increasing concentrations of drug until cells emerge that are resistant.
  In EGFR mutant lung cancer, this modeling has reliably identified clinically relevant EGFR tyrosine kinase (...)

• microscopic mimics of prostatic carcinoma

  5 June

  Benign Mimics of Prostate Cancer WebPathology
  Types
  partial atrophy of the prostate
  mucinous metaplasia
  atypical adenomatous hyperplasia
  Cowper glands
  post-atrophic hyperplasia (lobular atrophy)
  clear cell cribriform hyperplasia
  sclerosing adenosis
  prostatic xanthoma

• clear cell cribriform hyperplasia

  5 June

  clear cell cribriform hyperplasia of the prostate PO
  Definition: Clear cell cribriform hyperplasia is a form of nodular hyperplasia of the prostate without atypia.
  Synopsis
  Cribriform arrangement (glandular clusters with punched out lumens) of clear/pale eosinophilic cells with complex papillary growth simulating carcinoma.
  Conspicuous basal cells, small, uniform nuclei are associated.
  There is no prominent (...)

• ENs

  5 June

  Engrailed homeobox transcription factors
  Biomarker
  bladder cancer (#23434148#)
  Engrailed-2 (EN2) transcription factor is expressed in, and secreted by, bladder cancer cell lines and patient tumour specimens, justifying an evaluation of urinary
  EN2 as a diagnostic biomarker in bladder cancer using archived samples from an established biospecimen collection.
  In patients with NMIBC, urinary EN2 was detected in most cases with an overall sensitivity of 82% and specificity of 75%.
  The (...)

• EN2

  5 June

  Engrailed-2
  Biomarker
  bladder cancer (#23434148#)
  Engrailed-2 (EN2) transcription factor is expressed in, and secreted by, bladder cancer cell lines and patient tumour specimens, justifying an evaluation of urinary
  EN2 as a diagnostic biomarker in bladder cancer using archived samples from an established biospecimen collection.
  In patients with NMIBC, urinary EN2 was detected in most cases with an overall sensitivity of 82% and specificity of 75%.
  The sensitivity for stage Ta and (...)

• temozolomide

  4 June

  Temodar and Temodal and Temcad WP
  Temozolomide (brand names Temodar and Temodal and Temcad) is an oral alkylating agent used for the treatment of Grade IV astrocytoma — an aggressive brain tumor, also known as glioblastoma multiforme — as well as for treating melanoma, a form of skin cancer.
  Temozolomide is also indicated for relapsed Grade III anaplastic astrocytoma and not indicated for, but as of 2011 used to treat oligodendroglioma brain tumors in some countries, replacing the (...)

• pleural sarcoidosis

  3 June

  Sarcoidosis is a chronic disorder of unknown aetiology which causes tissue injury and granuloma formation in many organs. Although over 80% of cases have intrathoracic disease at presentation, pleural sarcoidosis remains an unusual manifestation.
  References
  Tommasini A, Di Vittorio G, Facchinetti F, Festi G, Schito V, Cipriani A. Pleural effusion in sarcoidosis: a case report. Sarcoidosis. 1994 Sep;11(2):138–140.
  Beekman JF, Zimmet SM, Chun BK, Miranda AA, Katz S. Spectrum of pleural (...)

• nodal sarcoidosis

  3 June

  Lymphadenopathy is very common in sarcoidosis. Intrathoracic nodes are enlarged in 75 to 90% of all patients; usually this involves the hilar nodes, but the paratracheal nodes are commonly involved.
  Peripheral lymphadenopathy is very common, particularly involving the cervical (the most common head and neck manifestation of the disease), axillary, epitrochlear, and inguinal nodes. Palpation causes no (...)

• DNA repair capacity

  3 June

  DRC
  DNA repair capacity (DRC) is a determinant not only of cancer development but also of individual response to therapy.
  Altered base and nucleotide excision repair (BER and NER) have been described in lymphocytes of patients with sporadic colorectal cancer.
  A study shows the feasibility of DRC evaluation in human solid tissues, representing a complex marker of multigene DNA repair processes.
  References
  Functional, genetic, and epigenetic aspects of base and nucleotide excision (...)

previous page | next page